Wolfgang Daum, PhD
Board of Directors
Wolfgang Daum, PhD - Executive Chairman
Wolfgang is Managing Partner of Carlyle Global Advisors after a successful career as serial entrepreneur in healthcare. He has developed a network of relationships with accomplished family offices in both the United States and internationally that share a passion for impact Investing and philanthropy in the life sciences and whom he advises from time to time in healthcare related investments. He has successfully helped build and exited from several life science companies to-date principally in the areas of neurological disease, cardiovascular disease and oncology related innovation. Wolfgang holds a M.S. in Physics from University of Gӧttingen and a PhD from Technical University Hamburg-Harburg, both in Germany. Wolfgang is also an active angel investor with Keiretsu in Palo Alto, CA.
Mark M. Davis, PhD
Mark M. Davis, PhD - Scientific Co-founder
Mark M. Davis, Ph.D. is Professor at Stanford University. He is well known for identifying the first T-cell receptor genes. He has authored over 350 publications and received numerous awards and honors for his work, including memberships in the National Academy of Sciences, The National Academy of Medicine and the Royal Society. He is an Investigator with the Howard Hughes Medical Institute and holds the Avery Family Chair of Immunology at the Stanford University School of Medicine. He has been vice chair and chair of the Department of Microbiology and Immunology at Stanford and, since 2004, The Director of the Institute for Immunity, Transplantation and Infection, which has become an international leader in the development of transformative technologies and approaches to better understanding the human immune system and its responses to infectious diseases and autoimmunity.Stanford
David Furman, PhD
& Chief Scientific Officer
Board of Directors
David Furman, PhD - Founder & Chief Scientific Officer
During his Postdoc, he conducted cutting-edge research in Data Science and Systems Immunology to answer scientific questions with strong potential for translational medicine, including the effect of immunity in aging and age-related disease. Advances in these areas will provide for improved diagnostic monitoring and therapeutic interventions that will significantly improve the health and lives of many people.
VP Investor Relations & Communications
Asli Gozoren - VP Investor Relations & Communications
Asli has over 20 years of experience in the finance industry, specifically in investor relations, corporate finance, and corporate development. Prior to joining Edifice Health Bio, Asli was a Partner at a San Francisco based advisory firm, guiding early stage companies in growth strategies focusing on key issues including cross-border expansion, commercialization, and capital raising initiatives. During her career, she managed the Corporate Finance division of UK based consulting firm Grant Thornton in an emerging market (led +100 clients in multi-million dollar M&A transactions, company valuations and due diligence projects), launched and grew the largest global business angel investment firm Keiretsu Forum to become the leading early stage investment venture in the MENAT region, an led key global initiatives to increase revenue through strategic partnerships and cross border portfolio syndications across the firm’s +50 global offices.
Krinx Kong, BBA
Executive VP, Sales & Marketing
Krinx Kong, BBA - Executive VP, Sales & Marketing
For the past 23 years, Krinx has been delivering results with leadership roles in commercial healthcare sales, marketing and business development, primarily in the areas of cardiovascular disease, oncology and clinical wellness. From being a sales manager/influencer for a mid-size pharma company KOS (acquired by Abbot for $1.5B), advising the C-Suite of hospital CEOs on sales strategy for the largest private hospital organization in the US (HCA) and to building the clinical sales department from the ground up at Boston Heart (acquired by Eurofins for $200M+), where he worked together with CEO Wolfgang Daum, he has made an impact on organizations at all levels. Krinx grew up in Dallas, TX and attended the University of Texas in Austin where he received his BBA in Marketing from the McCombs School of Business.
Zuzana Krejciova-Rajaniemi, PhD
Director of Translational Science
Zuzana Krejciova-Rajaniemi, PhD - Director of Translational Science
Zuzana transitioned to Edifice Health from being an Assistant Professional Researcher with Nobel Laureate Stanley Prusiner at UCSF, where she developed in vitro and in vivo models to explore the causes and underlying molecular pathways in neurodegenerative diseases and established readily scalable systems for facilitating drug discovery. Zuzana received her PhD from the National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences at the University of Edinburgh, United Kingdom. At the age of seventeen, Zuzana won the first silver medal awarded to a Slovak scientist at an International Environmental Olympiad. Occasionally she consults Epiona Ventures in San Francisco.UCSF
Anna Lau, MBA, CPA (inactive, FL)
Anna Lau, MBA, CPA (inactive, FL) - CFO
Anna is passionate about helping people. She applies over 20 years of corporate accounting and financial planning and analysis experience at Fortune 100 multinational companies with her executive education in strategy and marketing to help Iuve, her third healthtech startup, grow as an attractive investment. After starting her stock portfolio at Age 11, Anna is now an angel investor and limited partner of Portfolia. She plans and executes the financial roadmap for ambitious dreams for herself and entrepreneurs. Certificate of Excellence (venture capital, product management, strategy, leadership) from University of California at Berkeley, executive MBA with emphasis in strategy and marketing from University of North Carolina at Chapel Hill, inactive CPA, longtime caregiver.
Kari Nadeau, MD, PhD
Co-Founder & Scientific Advisor
Kari Nadeau, MD, PhD - Co-Founder and Scientific Advisor
Kari Nadeau is a Professor at Stanford University and is one of the nation’s foremost experts in adult and pediatric allergy and asthma. She is the Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Section Chief of Allergy and Asthma at the Stanford School of Medicine, and an endowed professor under the Naddisy Family Foundation. Dr. Nadeau received her MD and PhD from Harvard Medical School, completed a residency in pediatrics at Boston Children’s Hospital and a clinical fellowship in asthma and immunology at Stanford. After completing her residency, she spent 5 years in the biopharmaceutical industry, where she was instrumental in obtaining FDA approval for two biologics in the ﬁelds of autoimmunity and oncology, before starting her fellowship at Stanford. Dr. Nadeau has received honors and awards from the American Academy of Allergy, Asthma & Immunology; the American Lung Association; the Clinical Immunological Society; Food Allergy Research & Education (FARE); and the NIH. She has authored or co-authored more than 100 original papers focusing on understanding the factors responsible for the increased prevalence of allergies and asthma in the population, improving diagnostics, and understanding the immunological mechanisms underlying these diseases.Stanford
Robert Tibshirani, PhD
Robert Tibshirani, PhD - Scientific Advisor
Robert Tibshirani’s is Professor at Stanford University. His main interests are in applied statistics, biostatistics, and data mining. He is co-author of the books “Generalized Additive Models” (with Trevor Hastie, Stanford), “An Introduction to the Bootstrap” (with Brad Efron, Stanford), and “Elements of Statistical Learning” (with Trevor Hastie and Jerry Friedman, Stanford). His current research focuses on problems in biology and genomics, medicine, and industry. With Stanford collaborator Balasubramanian Narasimhan, he also develops software packages for genomics and proteomics. His most well-known contributions are in the field of Artificial Intelligence and he is sometimes referred to be the father of the field.Stanford
Eric Verdin, MD
Board Member & Scientific Advisor
Eric Verdin, MD - Board Member & Scientific Advisor
Eric is the president and chief executive officer of the Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctor of Medicine (MD) from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also a professor of medicine at University of California, San Francisco. Dr. Verdin joined the Buck in 2016 after spending the previous 20 years as a senior investigator at the Gladstone Institutes, where he served as associate director from 2004 to 2016.
Dr. Verdin’s laboratory focuses on the role of epigenetic regulators in the aging process. His laboratory was the first to clone a family of enzymes called HDACs, which regulate histone acetylation. Dr. Verdin studies how metabolism, diet, and small molecules regulate the activity of HDACs and sirtuins, and thereby the aging process itself and its associated diseases, including Alzheimer’s. He has published more than 210 scientific papers and holds more than 15 patents. He is a highly cited scientist and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He is an elected member of several scientific organizations, including the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians. He also serves on the advisory council of the National Institute on Drug Abuse at the NIH.
Joseph Wu, MD, PhD
Joseph Wu, MD, PhD - Scientific Advisor
Joseph C. Wu, MD, PhD is Director of the Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine and Radiology. Dr. Wu received his medical degree from Yale. He completed his medicine internship, residency and cardiology fellowship training at UCLA followed by a PhD (Molecular & Medical Pharmacology) in the UCLA STAR program. His clinical activities involve adult congenital heart disease and cardiovascular imaging. His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). Dr. Wu has published over 350 manuscripts with H-index of 91 on Google scholar. Among his trainees, 25 of them are principal investigators in the US or abroad. Dr. Wu has received numerous awards.Stanford Medicine